ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose ...
Nasdaq

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg, First Needle-Free Epinephrine Treatment for Children Ages 4 and Up

neffy 1 mg is the first approved needle-free epinephrine nasal spray for children aged 4 to 30 kg, addressing severe allergic reactions. ARS Pharmaceuticals announced the FDA approval of neffy 1 mg, ...
Nasdaq

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...
Seeking Alpha

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy ® (epinephrine nasal spray) 2mg for use in emergency treatment of ...
Monthly Prescribing Reference

Needle-Free Emergency Epinephrine Now Available for Pediatric Patients

Credit: ARS Pharmaceuticals. Each carton contains 2 blister packages each with a single-dose nasal spray product for 1 time use. It is recommended that patients be prescribed and have immediate access ...
Seeking Alpha

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from ...